Sign in
TerminatedPhase 1

Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

Key facts

Who runs it
Sanofi
Where
Houston, United StatesSee the siteAlso in 5 other countries, 10 sites
Status
Terminated
Phase
Phase 1
People taking part
44 people enrolled
Started
16 Aug 2021
Ended
15 Jan 2024
Type of study
Interventional, 5 groups
Treatments tested
  • SAR443216 IV
  • SAR443216 SC
Record updated
15 September 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Participants must be ≥ 18 years of age
  • Histologically or cytologically confirmed diagnosis of metastatic solid tumors
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • All participants should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion
  • Body weight within [45 - 150 kg] (inclusive)
  • All Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • Capable of giving signed informed consent

Who cannot take part

  • Prior solid organ or hematologic transplant
  • Participation in a concurrent clinical study in the treatment period
  • Any clinically significant cardiac disease
  • History of or current interstitial lung disease or pneumonitis
  • Uncontrolled or unresolved acute renal failure
  • Known positivity with human immunodeficiency virus (HIV), known active hepatitis A, B, and C, or uncontrolled chronic or ongoing infectious requiring parenteral treatment
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions; The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial
  • Receipt of a live-virus vaccination within 28 days of planned treatment start
  • Inadequate hematologic, hepatic and renal function

Where in United States

Also in 5 other countries, 10 sites

  • ~University of Texas - MD Anderson Cancer Center Site Number : 8400002Houston, United States

About the trial

What the trial wants to find out

Primary Objectives:

Read full original descriptionShow less

Part 1 (Dose Escalation)

* To determine the MTD/maximum administered dose (MAD) of SAR443216 administered as a single agent in participants with HER2 expressing solid tumors and determine the RD(s) for intravenous (IV) and subcutaneous (SC) administration in the dose escalation part. * To determine the safety of SAR443216 after intravenous (IV) and subcutaneous (SC) administration.

Part 2 (Dose expansion)

• To assess preliminary clinical activity of single agent SAR443216 at the RD(s) in participants with HER2 expressing solid tumors, with various levels of HER2 expression.

Secondary Objectives:

Part 1 • To assess preliminary clinical activity of single agent SAR443216 after IV and SC administration at the RD(s) in participants with HER2 expressing solid tumors, with various levels of HER2 expression.

Part 2

• To determine the safety of SAR443216.

Part 1 and 2

* To characterize the pharmacokinetic (PK) profile of SAR443216 when administered as a single agent after IV and SC (Part 1 only) administration. * To evaluate the immunogenicity of SAR443216 after IV and SC administration. * To assess preliminary clinical activity of single agent SAR443216 at the RD(s) in participants with HER2 expressing solid tumors, with various levels of HER2 expression.

The 5 groups in the trial

  • SAR443216-Dose EscalationTreatment being tested

    Participants with metastatic solid tumors that express HER2 in tumor tissue and/or with HER2 aberration will receive SAR443216 as intravenous (IV) infusion or subcutaneous (SC) injection.

    Treatment: SAR443216 IV and SAR443216 SC

  • SAR443216-Dose Expansion - metastatic breast cancers with HER2 high expression: Cohort ATreatment being tested

    Participants with metastatic breast cancers with HER2 high expression (with amplification) will receive SAR443216 as intravenous (IV) infusion.

    Treatment: SAR443216 IV

  • SAR443216-Dose Expansion- metastatic breast cancers with HER2 low expression: Cohort BTreatment being tested

    Participants with metastatic breast cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.

    Treatment: SAR443216 IV

  • SAR443216-Dose Expansion- metastatic gastric cancers with HER2 low expression: Cohort CTreatment being tested

    Participants with metastatic gastric cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.

    Treatment: SAR443216 IV

  • SAR443216-Dose Expansion - metastatic NSCLC with HER2 low or high expression: Cohort DTreatment being tested

    Participants with metastatic NSCLC with HER2 low or high expression and/or HER2 mutation will receive SAR443216 as intravenous (IV) infusion.

    Treatment: SAR443216 IV

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1/1b Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors.
Record updated
15 September 2025